10-Q/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-Q/A

(Amendment No. 1)

Quarterly Report Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the Quarterly Period Ended March 31, 2014

AMSURG CORP.

(Exact Name of Registrant as Specified in its Charter)

Tennessee	000-22217	62-1493316
(State or Other Jurisdiction of Incorporation)	(Commission  File Number)	(I.R.S. Employer  Identification No.)
20 Burton Hills Boulevard
Nashville, Tennessee		37215
(Address of Principal Executive Offices)		(Zip Code)

 (615) 665-1283

(Registrant’s Telephone Number, Including Area Code)

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]                   No [  ]

        Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X]                   No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.   (Check one):

                                Large accelerated filer  [X]                                      Accelerated filer                  [  ]

Non-accelerated filer    [   ]                                      Smaller reporting company [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ]                    No [X]

As of April 30, 2014 there were outstanding 32,531,056 shares of the registrant’s Common Stock, no par value.

Explanatory Note

AmSurg Corp. (the "Company") is filing this Amendment No. 1 (this "Amendment") to its Quarterly Report on Form 10-Q for the three months ended March 31, 2014, filed with the Securities and Exchange Commission on May 1, 2014 (the "Original Filing"), for the sole purpose of furnishing the Interactive Data File as Exhibit 101. The Company attempted to file Exhibit 101 on its initial Form 10-Q filing for the period ended March 31, 2014.  However, Exhibit 101 was not accepted by the Securities and Exchange Commission due to a validation error in the electronic file.

Other than as described above, no changes have been made to the Original Filing. This Amendment speaks as of the date of the Original Filing, does not reflect subsequent events that may have occurred after the date of the Original Filing and does not modify or update in any way any disclosures made in the Original Filing.

1

Item 6.        Exhibits

10.1*   Form of Indemnification Agreement with directors, executive officers and advisors (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, dated February 4, 2014)

10.2*   Third Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Claire M. Gulmi (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, dated February 4, 2014)

10.3*   Third Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and David L. Manning (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K, dated February 4, 2014)

10.4*   Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Phillip A. Clendenin (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K, dated February 4, 2014)

10.5*   Amended and Restated Employment Agreement, dated January 30, 2014, between AmSurg and Kevin D. Eastridge (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K, dated February 4, 2014)

31.1** Certification of President and Chief Executive Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2** Certification of Executive Vice President and Chief Financial Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1** Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101**  Interactive data files pursuant to Rule 405 of Regulation S-T: (i) the Consolidated Balance Sheets at March 31, 2014 and December 31, 2013, (ii) the Consolidated Statements of Earnings and Comprehensive Income for the three month periods ended March 31, 2014 and 2013, (iii) the Consolidated Statements of Changes in Equity for the three month periods ended March 31, 2014 and 2013, (iv) the Consolidated Statements of Cash Flows for the three month periods ended March 31, 2014 and 2013 and (v) the notes to the Unaudited Consolidated Financial Statements for the three month periods ended March 31, 2014 and 2013.

*      Previously filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed on May 1, 2014.

**    Furnished herewith.

2

Signature

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMSURG CORP.
Date:  May 1, 2014
	By:	/s/ Claire M. Gulmi
		Claire M. Gulmi
		Executive Vice President and
		Chief Financial Officer
		(Principal Financial and Duly Authorized Officer)

3

EX-31.1

 

Exhibit 31.1

Certifications

I, Christopher A. Holden, certify that:

1.     I have reviewed this quarterly report on Form 10-Q/A of AmSurg Corp.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:    May 1, 2014

By:	/s/ Christopher A. Holden
Name:	Christopher A. Holden
Title:	President and Chief Executive Officer

EX-31.2

 

Exhibit 31.2

Certifications

I, Claire M. Gulmi, certify that:

1.     I have reviewed this quarterly report on Form 10-Q/A of AmSurg Corp.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:    May 1, 2014

By:	/s/ Claire M. Gulmi
Name:	Claire M. Gulmi
Title:	Executive Vice President and
	Chief Financial Officer

EX-32

 

Exhibit 32.1

AMSURG CORP.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AmSurg Corp. (the “Company”) on Form 10-Q/A for the period ending March 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Christopher A. Holden

Christopher A. Holden

President and Chief Executive

Officer of the Company

May 1, 2014

/s/ Claire M. Gulmi

Claire M. Gulmi

Executive Vice President and

Chief Financial Officer of the Company

May 1, 2014

XML

Acquisitions (Revs and Earnings) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Business Acquisition [Line Items]
Net earnings (loss)	$ 60,114	$ 62,273
Less: Net earnings attributable to noncontrolling interests	42,919	44,462
Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	17,195	17,811
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Revenues	1,031	0
Net earnings (loss)	245	0
Less: Net earnings attributable to noncontrolling interests	151	0
Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$ 94	$ 0

XML

Shareholder's Equity (Schedule of Stock Option Activity (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Shareholders' Equity
Outstanding at beginning of period, Number of Shares	270,464
Options exercised, Number of Shares	(19,921)
Options terminated, Number of Shares	0
Outstanding at end of period, Number of Shares	250,543	270,464
Vested or expected to vest at end of period, Number of Shares	250,543
Exercisable at end of period, Number of Shares	250,543
Outstanding at beginning of period, Weighted Average Exercise Price	$ 23.16
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 24.49
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 0
Outstanding at end of period, Weighted Average Exercise Price	$ 23.05	$ 23.16
Vested or expected to vest at end of period, weighted average exercise price	$ 23.05
Exercisable at end of period, Weighted Average Exercise Price	$ 23.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term, Period Start	2 years 2 months 12 days	2 years 6 months 0 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term, Period End	2 years 2 months 12 days	2 years 6 months 0 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	2 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	2 years 2 months 12 days

XML

Long Term Debt (Current & Noncurrent Breakout) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Debt Disclosure Current [Abstract]
Long-term debt	$ 564,937	$ 583,298
Less current portion	20,285	20,844
Long-term debt, gross	$ 585,222	$ 604,142

XML

Shareholder's Equity (Schedule of Stock Option Activity (Parenthetical) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Shareholders' Equity
Total intrinsic value with options exercised	$ 488,000
Aggregate intrinsic value of options outstanding	6,020,000
Total intrinsic value of options vested or expected to vest	6,020,000
Total Intrinsic value of options exercisable	$ 6,020,000

XML

Long-Term Debt (Narrative) (Details) (USD $)			3 Months Ended				3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014 Line of Credit [Member]	Mar. 31, 2014 Unsecured Debt [Member]	Mar. 31, 2014 Secured Debt [Member]	May 28, 2010 Secured Debt [Member]	Mar. 31, 2014 Maximum [Member] Line of Credit [Member]	Mar. 31, 2014 Minimum [Member] Line of Credit [Member]	Mar. 31, 2014 Period from current report date to November 30, 2015 Unsecured Debt [Member]	Mar. 31, 2014 Period from January 1, 2012 through November 7, 2012 Secured Debt [Member]
Credit Facility
Borrowing capacity of new revolving credit agreement			$ 475,000,000
Line of Credit Facility, Expiration Date			Jun. 01, 2018
Debt instruments interest rate base rate plus							1.00%	0.25%
Debt instruments interest rate Libor plus							2.00%	1.25%
Unused capacity commitment fee, percentage							0.40%	0.25%
Senior Unsecured Debt
Unsecured Debt	250,000,000	250,000,000
Debt Instrument, Interest Rate, Stated Percentage				5.625%	8.04%					6.04%
Debt Instrument, Maturity Date				Nov. 30, 2020	May 28, 2020
Redeemable Principal Percentage				35.00%
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount									105.625%
Senior Secured Debt
Senior Secured Notes	$ 66,964,000	$ 69,643,000				$ 75,000,000
Debt Instrument, Interest Rate, Stated Percentage				5.625%	8.04%					6.04%
Debt Instrument, Maturity Date				Nov. 30, 2020	May 28, 2020

XML

Guarantor (Tables)

3 Months Ended

Mar. 31, 2014

Condensed Consolidating Financial Information

Condensed Balance Sheet

Condensed Consolidating Balance Sheet - March 31, 2014 (In thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	5,562	$	-	$	41,554	$	-	$	47,116
	Accounts receivable, net				-		-		106,209		-		106,209
	Supplies inventory				52		-		18,381		-		18,433
	Deferred income taxes				1,026		-		-		-		1,026
	Prepaid and other current assets				28,618		-		13,350		(4,817)		37,151
		Total current assets			35,258		-		179,494		(4,817)		209,935
Property and equipment, net					10,129		-		158,877		-		169,006
Investments in unconsolidated affiliates and other					1,489,635		1,458,185		-		(2,928,336)		19,484
Goodwill and intangible assets, net					20,185		-		909		1,764,622		1,785,716
			Total assets	$	1,555,207	$	1,458,185	$	339,280	$	(1,168,531)	$	2,184,141
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	10,714	$	-	$	9,571	$	-	$	20,285
	Accounts payable				1,014		-		28,972		(4,627)		25,359
	Accrued liabilities				24,092		-		14,703		(190)		38,605
		Total current liabilities			35,820		-		53,246		(4,817)		84,249
Long-term debt					543,750		-		52,009		(30,822)		564,937
Deferred income taxes					185,882		-		-		-		185,882
Other long-term liabilities					7,342		-		18,411		-		25,753
Noncontrolling interests – redeemable					-		-		63,691		113,992		177,683
Equity:
		Total AmSurg Corp. equity			782,413		1,458,185		113,448		(1,571,633)		782,413
		Noncontrolling interests – non-redeemable			-		-		38,475		324,749		363,224
		Total equity			782,413		1,458,185		151,923		(1,246,884)		1,145,637
			Total liabilities and equity	$	1,555,207	$	1,458,185	$	339,280	$	(1,168,531)	$	2,184,141

Condensed Consolidating Balance Sheet - December 31, 2013 (In thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	6,710	$	-	$	44,130	$	-	$	50,840
	Accounts receivable, net				-		-		105,072		-		105,072
	Supplies inventory				33		-		18,381		-		18,414
	Deferred income taxes				3,097		-		-		-		3,097
	Prepaid and other current assets				23,993		-		13,971		(4,362)		33,602
		Total current assets			33,833		-		181,554		(4,362)		211,025
Property and equipment, net					9,829		-		160,066		-		169,895
Investments in unconsolidated affiliates and other					1,484,974		1,453,596		-		(2,922,178)		16,392
Goodwill and intangible assets, net					20,684		-		978		1,758,970		1,780,632
			Total assets	$	1,549,320	$	1,453,596	$	342,598	$	(1,167,570)	$	2,177,944
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	10,714	$	-	$	10,130	$	-	$	20,844
	Accounts payable				1,972		-		29,487		(3,958)		27,501
	Accrued liabilities				27,419		-		14,510		(404)		41,525
		Total current liabilities			40,105		-		54,127		(4,362)		89,870
Long-term debt					561,429		-		53,246		(31,377)		583,298
Deferred income taxes					176,020		-		-		-		176,020
Other long-term liabilities					7,569		-		17,934		-		25,503
Noncontrolling interests – redeemable					-		-		63,704		113,993		177,697
Equity:
		Total AmSurg Corp. equity			764,197		1,453,596		114,671		(1,568,267)		764,197
		Noncontrolling interests – non-redeemable			-		-		38,916		322,443		361,359
		Total equity			764,197		1,453,596		153,587		(1,245,824)		1,125,556
			Total liabilities and equity	$	1,549,320	$	1,453,596	$	342,598	$	(1,167,570)	$	2,177,944

Condensed Income Statement

Condensed Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2014 (In thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues				$	6,127	$	-	$	261,589	$	(4,609)	$	263,107
Operating expenses:
	Salaries and benefits				14,485		-		68,830		(121)		83,194
	Supply cost				-		-		38,720		-		38,720
	Other operating expenses				4,166		-		55,591		(4,488)		55,269
	Depreciation and amortization				825		-		7,549		-		8,374
		Total operating expenses			19,476		-		170,690		(4,609)		185,557
Gain on deconsolidation					2,045		2,045		-		(2,045)		2,045
Equity in earnings of unconsolidated affiliates					48,052		48,052		-		(95,340)		764
		Operating income			36,748		50,097		90,899		(97,385)		80,359
Interest expense					6,452		-		511		-		6,963
	Earnings from continuing operations before income taxes				30,296		50,097		90,388		(97,385)		73,396
Income tax expense					12,704		-		353		-		13,057
	Net earnings from continuing operations				17,592		50,097		90,035		(97,385)		60,339
	Net earnings (loss) from discontinued operations				(397)		-		172		-		(225)
		Net earnings and comprehensive income			17,195		50,097		90,207		(97,385)		60,114
Less net earnings and comprehensive income attributable to noncontrolling interests:
	Net earnings from continuing operations				-		-		42,835		-		42,835
	Net earnings from discontinued operations				-		-		84		-		84
		Total net earnings and comprehensive income attributable to noncontrolling interests			-		-		42,919		-		42,919
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$	17,195	$	50,097	$	47,288	$	(97,385)	$	17,195
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax			$	17,592	$	50,097	$	47,200	$	(97,385)	$	17,504
	Discontinued operations, net of income tax				(397)		-		88		-		(309)
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$	17,195	$	50,097	$	47,288	$	(97,385)	$	17,195

Condensed Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2013 (In thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues				$	5,716	$	-	$	256,711	$	(4,238)	$	258,189
Operating expenses:
	Salaries and benefits				15,421		-		65,650		(113)		80,958
	Supply cost				-		-		37,213		-		37,213
	Other operating expenses				5,060		-		51,792		(4,125)		52,727
	Depreciation and amortization				772		-		7,236		-		8,008
		Total operating expenses			21,253		-		161,891		(4,238)		178,906
Gain on deconsolidation					2,237		2,237		-		(2,237)		2,237
Equity in earnings of unconsolidated affiliates					49,955		49,955		-		(99,508)		402
		Operating income			36,655		52,192		94,820		(101,745)		81,922
Interest expense					6,923		-		619		-		7,542
	Earnings from continuing operations before income taxes				29,732		52,192		94,201		(101,745)		74,380
Income tax expense					11,877		-		392		-		12,269
	Net earnings from continuing operations				17,855		52,192		93,809		(101,745)		62,111
	Net earnings (loss) from discontinued operations				(44)		-		206		-		162
		Net earnings and comprehensive income			17,811		52,192		94,015		(101,745)		62,273
Less net earnings and comprehensive income attributable to noncontrolling interests:
	Net earnings from continuing operations				-		-		44,361		-		44,361
	Net earnings from discontinued operations				-		-		101		-		101
		Total net earnings and comprehensive income attributable to noncontrolling interests			-		-		44,462		-		44,462
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$	17,811	$	52,192	$	49,553	$	(101,745)	$	17,811
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax			$	17,855	$	52,192	$	49,448	$	(101,745)	$	17,750
	Discontinued operations, net of income tax				(44)		-		105		-		61
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$	17,811	$	52,192	$	49,553	$	(101,745)	$	17,811

Condensed Cash Flow Statement

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2014 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by operating activities	$	18,482	$	48,096	$	96,257	$	(93,016)	$	69,819
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(5,082)		-		44		(5,038)
	Acquisition of property and equipment			(1,237)		-		(5,801)		-		(7,038)
	Proceeds from sale of interests in surgery centers			-		1,111		-		-		1,111
	Other			(629)		211		-		-		(418)
		Net cash flows used in investing activities		(1,866)		(3,760)		(5,801)		44		(11,383)
Cash flows from financing activities:
	Proceeds from long-term borrowings			30,000		-		1,945		-		31,945
	Repayment on long-term borrowings			(47,679)		-		(3,174)		-		(50,853)
	Distributions to owners, including noncontrolling interests			-		(44,920)		(91,290)		93,016		(43,194)
	Changes in intercompany balances with affiliates, net			556		-		(556)		-		-
	Other financing activities, net			(641)		584		43		(44)		(58)
		Net cash flows used in financing activities		(17,764)		(44,336)		(93,032)		92,972		(62,160)
Net decrease in cash and cash equivalents				(1,148)		-		(2,576)		-		(3,724)
Cash and cash equivalents, beginning of period				6,710		-		44,130		-		50,840
Cash and cash equivalents, end of period			$	5,562	$	-	$	41,554	$	-	$	47,116

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2013 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by operating activities	$	23,940	$	49,577	$	99,411	$	(99,063)	$	73,865
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(242)		-		(10)		(252)
	Acquisition of property and equipment			(853)		-		(5,257)		-		(6,110)
		Net cash flows used in investing activities		(853)		(242)		(5,257)		(10)		(6,362)
Cash flows from financing activities:
	Proceeds from long-term borrowings			29,700		-		1,170		-		30,870
	Repayment on long-term borrowings			(45,024)		-		(3,187)		-		(48,211)
	Distributions to owners, including noncontrolling interests			-		(49,486)		(93,491)		99,063		(43,914)
	Changes in intercompany balances with affiliates, net			533		-		(533)		-		-
	Other financing activities, net			(10,792)		151		398		10		(10,233)
		Net cash flows used in financing activities		(25,583)		(49,335)		(95,643)		99,073		(71,488)
Net decrease in cash and cash equivalents				(2,496)		-		(1,489)		-		(3,985)
Cash and cash equivalents, beginning of period				7,259		-		39,139		-		46,398
Cash and cash equivalents, end of period			$	4,763	$	-	$	37,650	$	-	$	42,413

XML

Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2014 Y
Business Combination, Contingent Consideration Arrangements [Abstract]
Contractual Obligation Term	15
Contractual Obligation Lease Square Footage	110,000
Contractual Obligation Annual Rental Payment	$ 2,300,000
Contractual Obligation Annual Rental Payment Increase	1.90%
Contractual Obligation Maximum Tenant Allowance	$ 4,400,000

XML

Acquisition (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Acquisition and Investments in Unconsolidated Affiliates

As a significant part of its growth strategy, the Company primarily acquires controlling interests in centers. The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value.

XML

Fair Value Measurements (Narrative) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Long-term Debt gross	$ 585,222,000	$ 604,142,000
Fixed Interest Rate [Member]
Long-term Debt gross	345,253,000
Long-term Debt, Fair Value	365,111,000
Variable Interest Rate [Member]
Long-term Debt gross	239,969,000
Long-term Debt, Fair Value	239,969,000
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Supplemental executive retirement savings plan investments - Level 2	$ 16,175,000	$ 13,313,000

XML

Dispositions (Results Of Operations Of Combined Discontinued Surgery Centers) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Dispositions
Revenues	$ 1,048	$ 1,872
Earnings before income taxes	172	209
Net earnings	$ 137	$ 162

XML

Acquisitions (Narrative) (Details) (USD $)	3 Months Ended			3 Months Ended				0 Months Ended
	Mar. 31, 2014 Centers	Mar. 31, 2013 Centers	Dec. 31, 2013	Mar. 31, 2014 Noncontrolling Interest Number Of Centers [Member] Centers	Mar. 31, 2013 Noncontrolling Interest Number Of Centers [Member] Centers	Mar. 31, 2014 Controlling Interest [Member] Centers	Mar. 31, 2013 Controlling Interest [Member] Centers	Sep. 01, 2011 Acquired Nsc Centers [Member] Centers	Mar. 31, 2013 Acquired Nsc Centers [Member]	Mar. 31, 2014 Current Year Acquisitions [Member]	Mar. 31, 2013 Current Year Acquisitions [Member]
Business Acquisition [Line Items]
Equity Method Investments	$ 19,484,000		$ 16,392,000							$ 1,238,000	$ 5,200,000
Gain (loss) on deconsolidation	2,045,000	2,237,000
Number of business acquisitions				1	1	1	0	17
Payments to Acquire Businesses, Net of Cash Acquired	5,038,000	252,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High								7,500,000
Contingent Purchase Price Obligation, Settlement Amount									2,744,000
Goodwill deductible for tax purposes	4,670,000	0
Proceeds from Divestiture of Interest in Consolidated Subsidiaries	$ 600,000
Number Of Consolidated Centers Contributed To Joint Venture	1	1

XML

Shareholders' Equity (Share-Based Activity) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Shareholders' Equity
Share-based compensation expense	$ 2,458	$ 2,050
Fair value of shares vested	9,175	9,182
Cash received from option exercises	488	5,691
Tax benefit from option exercises	$ 1,727	$ 288

XML

Guarantor (Cash Flow Statements) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net cash flows provided by operating activities	$ 69,819	$ 73,865
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	(5,038)	(252)
Acquisition of property and equipment	(7,038)	(6,110)
Proceeds from sale of interests in surgery centers	1,111	0
Other	(418)	0
Net cash flows used in investing activities	(11,383)	(6,362)
Cash flows from financing activities:
Proceeds from long-term borrowings	31,945	30,870
Repayment on long-term borrowings	(50,853)	(48,211)
Distributions to noncontrolling interests	(43,194)	(43,914)
Net cash flows provided by (used in) financing activities	(62,160)	(71,488)
Net increase (decrease) in cash and cash equivalents	(3,724)	(3,985)
Cash and cash equivalents, beginning of period	50,840	46,398
Cash and cash equivalents, end of period	47,116	42,413
Consolidation, Eliminations [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	(93,016)	(99,063)
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	44	(10)
Acquisition of property and equipment	0	0
Proceeds from sale of interests in surgery centers	0	0
Other	0	0
Net cash flows used in investing activities	44	(10)
Cash flows from financing activities:
Proceeds from long-term borrowings	0	0
Repayment on long-term borrowings	0	0
Distributions to noncontrolling interests	93,016	99,063
Capital contributions	0
Changes In Intercompany Balances	0	0
Other financing activities, net	(44)	10
Net cash flows provided by (used in) financing activities	92,972	99,073
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Parent Company [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	18,482	23,940
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	0	0
Acquisition of property and equipment	(1,237)	(853)
Proceeds from sale of interests in surgery centers	0	0
Other	(629)	0
Net cash flows used in investing activities	(1,866)	(853)
Cash flows from financing activities:
Proceeds from long-term borrowings	30,000	29,700
Repayment on long-term borrowings	(47,679)	(45,024)
Distributions to noncontrolling interests	0	0
Capital contributions	0
Changes In Intercompany Balances	556	533
Other financing activities, net	(641)	(10,792)
Net cash flows provided by (used in) financing activities	(17,764)	(25,583)
Net increase (decrease) in cash and cash equivalents	(1,148)	(2,496)
Cash and cash equivalents, beginning of period	6,710	7,259
Cash and cash equivalents, end of period	5,562	4,763
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	48,096	49,577
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	(5,082)	(242)
Acquisition of property and equipment	0	0
Proceeds from sale of interests in surgery centers	1,111	0
Other	211	0
Net cash flows used in investing activities	(3,760)	(242)
Cash flows from financing activities:
Proceeds from long-term borrowings	0	0
Repayment on long-term borrowings	0	0
Distributions to noncontrolling interests	(44,920)	(49,486)
Capital contributions	0
Changes In Intercompany Balances	0	0
Other financing activities, net	584	151
Net cash flows provided by (used in) financing activities	(44,336)	(49,335)
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	96,257	99,411
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	0	0
Acquisition of property and equipment	(5,801)	(5,257)
Proceeds from sale of interests in surgery centers	0	0
Other	0	0
Net cash flows used in investing activities	(5,801)	(5,257)
Cash flows from financing activities:
Proceeds from long-term borrowings	1,945	1,170
Repayment on long-term borrowings	(3,174)	(3,187)
Distributions to noncontrolling interests	(91,290)	(93,491)
Capital contributions	0
Changes In Intercompany Balances	(556)	(533)
Other financing activities, net	43	398
Net cash flows provided by (used in) financing activities	(93,032)	(95,643)
Net increase (decrease) in cash and cash equivalents	(2,576)	(1,489)
Cash and cash equivalents, beginning of period	44,130	39,139
Cash and cash equivalents, end of period	41,554	37,650
Consolidated Entities [Member]
Cash flows from financing activities:
Changes In Intercompany Balances	0	0
Other financing activities, net	$ (58)	$ (10,233)

XML

Long-Term Debt (Components Of Long-Term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Long-Term Debt
Revolving credit agreement	$ 237,500	$ 252,500
Senior Unsecured Notes	250,000	250,000
Senior Secured Notes	66,964	69,643
Other debt	20,193	21,149
Capitalized lease arrangements	10,565	10,850
Long-term debt, gross	$ 585,222	$ 604,142

XML

Revenue Recognition

3 Months Ended

Mar. 31, 2014

Revenue Recognition

Revenue Recognition

(3) Revenue Recognition

Center revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, atcertain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from centers are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During each of the three months ended March 31, 2014 and 2013, the Company derived approximately 25% of its revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs. Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

XML

Goodwill And Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Goodwill And Intangible Assets
Amortization of Intangible Assets	$ 569,000	$ 545,000
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	1,682,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	2,241,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two	2,240,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three	1,986,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	1,423,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five	859,000
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	837,000
Finite-Lived Intangible Asset, Useful Life	5 years 6 months 0 days
Restrictive Covenant Agreements	$ 9,825,000		$ 9,825,000

XML

Goodwill And Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2014

Goodwill And Intangible Assets

Changes In Carrying Amount Of Goodwill

Balance as of December 31, 2013	$	1,758,970
Goodwill acquired, including post acquisition adjustments		8,328
Goodwill disposed, including impact of deconsolidation transaction		(2,675)
Balance as of March 31, 2014	$	1,764,623

Schedule of Finite-Lived Intangible Assets

		March 31, 2014						December 31, 2013
		Gross						Gross
		Carrying		Accumulated				Carrying		Accumulated
		Amount		Amortization		Net		Amount		Amortization		Net
Deferred financing cost		$	15,814	$	(5,452)	$	10,362	$	15,814	$	(4,953)	$	10,861
Agreements, contracts and other intangible assets			3,448		(2,542)		906		3,448		(2,472)		976
	Total amortizable intangible assets	$	19,262	$	(7,994)	$	11,268	$	19,262	$	(7,425)	$	11,837

XML

Dispositions (Tables)

3 Months Ended

Mar. 31, 2014

Dispositions

Results Of Operations Of Centers Discontinued

	Three Months Ended March 31,
	2014		2013
Cash proceeds from disposal	$	1,147	$	-
Net (loss) earnings from discontinued operations		(225)		162
Net (loss) earnings from discontinued operations attributable to AmSurg Corp.		(309)		61

Results Of Operations Of Combined Discontinued Surgery Centers

	Three Months Ended March 31,
	2014		2013
Revenues	$	1,048	$	1,872
Earnings before income taxes		172		209
Net earnings		137		162

XML

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Shareholders' Equity
Net earnings from continuing operations attributable to AmSurg Corp., Earnings (Numerator)	$ 17,504	$ 17,750
Net earnings attributable to AmSurg Corp., Earnings (Numerator)	$ 17,195	$ 17,811
Net earnings from continuing operations attributable to AmSurg Corp. (Basic), Shares (Denominator)	31,716	31,217
Net earnings from continuing operations attributable to AmSurg Corp. (Diluted), Shares (Denominator)	32,120	31,881
Dilutive Securities, Effect on Basic Earnings Per Share	404	664
Net earnings from continuing operations attributable to AmSurg Corp. per common share (Basic), Per Share Amount	$ 0.55	$ 0.57
Net earnings from continuing operations attributable to AmSurg Corp. per common share (Diluted), Per Share Amount	$ 0.55	$ 0.56
Net earnings attributable to AmSurg Corp. per common share (Basic), Per Share Amount	$ 0.54	$ 0.57
Net earnings attributable to AmSurg Corp. per common share (Diluted), Per Share Amount	$ 0.54	$ 0.56

XML

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets
Balance, beginning of period	$ 1,758,970
Goodwill acquired, including post acquisition adjustments	8,328
Disposals	(2,675)
Balance, end of period	$ 1,764,623

XML

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2014

Long-Term Debt

Components Of Long-Term Debt

		March 31,		December 31,
		2014		2013
Revolving credit agreement		$	237,500	$	252,500
Senior Unsecured Notes due 2020 (5.625%)			250,000		250,000
Senior Secured Notes due 2020 (8.04%)			66,964		69,643
Other debt due through 2025			20,193		21,149
Capitalized lease arrangements due through 2026			10,565		10,850
			585,222		604,142
Less current portion			20,285		20,844
	Long-term debt	$	564,937	$	583,298

Redemption Price Percentage

Period	Redemption Price
2015	104.219%
2016	102.813%
2017	101.406%
2018 and thereafter	100.000%

XML

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2014

Shareholders' Equity

Share-Based Activity

	Three Months Ended March 31,
	2014		2013
Share-based compensation expense	$	2,458	$	2,050
Fair value of shares vested		9,175		9,182
Cash received from option exercises		488		5,691
Tax benefit from option exercises		1,727		288

Schedule Of Changes In Non-Vested Restricted Shares

			Weighted
		Number	Average
		of Shares	Grant Price
Non-vested shares at December 31, 2013		743,869	$	26.54
	Shares granted	200,391		42.38
	Shares vested	(218,405)		21.62
Non-vested shares at March 31, 2014		725,855	$	32.40

Schedule Of Stock Option Activity

					Weighted
					Average
			Weighted		Remaining
		Number	Average		Contractual
		of Shares	Exercise Price		Term (in years)
Outstanding at December 31, 2013		270,464	$	23.16	2.5
	Options exercised with total intrinsic value of $488,000	(19,921)		24.49
Outstanding at March 31, 2014 with aggregate intrinsic value of $6,020,000		250,543	$	23.05	2.2
Vested at March 31, 2014 with aggregate intrinsic value of $6,020,000		250,543	$	23.05	2.2
Exercisable at March 31, 2014 with aggregate intrinsic value of $6,020,000		250,543	$	23.05	2.2

Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share

		Three Months Ended March 31,
		Earnings		Shares	Per Share
		(Numerator)		(Denominator)	Amount
2014:
Net earnings from continuing operations attributable to AmSurg Corp. per common share (basic)		$	17,504	31,716	$	0.55
Effect of dilutive securities options and non-vested shares			-	404
	Net earnings from continuing operations attributable to AmSurg Corp. per common share (diluted)	$	17,504	32,120	$	0.55
Net earnings attributable to AmSurg Corp. per common share (basic)		$	17,195	31,716	$	0.54
Effect of dilutive securities options and non-vested shares			-	404
	Net earnings attributable to AmSurg Corp. per common share (diluted)	$	17,195	32,120	$	0.54
2013:
Net earnings from continuing operations attributable to AmSurg Corp. per common share (basic)		$	17,750	31,217	$	0.57
Effect of dilutive securities options and non-vested shares			-	664
	Net earnings from continuing operations attributable to AmSurg Corp. per common share (diluted)	$	17,750	31,881	$	0.56
Net earnings attributable to AmSurg Corp. per common share (basic)		$	17,811	31,217	$	0.57
Effect of dilutive securities options and non-vested shares			-	664
	Net earnings attributable to AmSurg Corp. per common share (diluted)	$	17,811	31,881	$	0.56

XML

Use of Estimates

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Use of Estimates

(2) Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The determination of contractual and bad debt allowances constitutes a significant estimate. Some of the factors considered by management in determining the amount of such allowances are the historical trends of the centers’ cash collections and contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics. Accordingly, net accounts receivable at March 31, 2014 and December 31, 2013 reflect allowances for contractual adjustments of $280,582,000 and $289,937,000, respectively, and allowances for bad debt expense of $29,120,000 and $27,862,000, respectively. For the three months ended March 31, 2014 and 2013, bad debt expense from continuing operations was approximately $5,208,000 and $5,900,000, respectively, and is included in other operating expenses in the accompanying consolidated statements of earnings and comprehensive income.

XML

Supplemental Cash Flow Information (Tables)

3 Months Ended

Mar. 31, 2014

Supplemental Cash Flow Information

Summary Of Supplemental Cash Flow Information

		Three Months Ended March 31,
		2014		2013
Cash paid during the period for:
	Interest	$	3,132	$	3,547
	Income taxes, net of refunds		65		69
Non-cash investing and financing activities:
	Increase (decrease) in accounts payable associated with acquisition of property and equipment		1,111		(675)
	Capital lease obligations		116		-

XML

Acquisitions (Consolidated Pro Forma Results Of Acquisition) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Business Combinations [Abstract]
Revenues	$ 263,107	$ 270,371
Net earnings	60,114	65,385
Amounts Attributable To Common Shareholders
Net earnings from continuing operations	17,504	18,830
Net earnings	$ 17,195	$ 18,891
Net earnings from continuing operations per common share: Basic	$ 0.55	$ 0.6
Net earnings from continuing operations per common share: Diluted	$ 0.54	$ 0.59
Net earnings: Basic	$ 0.54	$ 0.61
Net earnings: Diluted	$ 0.54	$ 0.59
Weighted average number of shares and share equivalents: Basic	31,716	31,217
Weighted average number of shares and share equivalents: Diluted	32,120	31,881

XML

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Shareholders' Equity
Non-vested shares at beginning of period, Number of Shares	743,869
Non-vested shares at beginning of period, Weighted Average Grant Price	$ 26.54
Shares granted, Number of Shares	200,391
Shares granted, Weighted Average Grant Price	$ 42.38
Shares vested, net of shares repurchased to cover tax withholding requirements,, Number of Shares	(218,405)
Shares vested, net of shares repurchased to cover tax withholding requirements, , Weighted Average Grant Price	$ 21.62
Shares forfeited, Number of Shares	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 0
Non-vested shares at end of period, Number of Shares	725,855
Non-vested shares at end of period, Weighted Average Grant Price	$ 32.4

XML

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Assets
Cash and cash equivalents	$ 47,116,000	$ 50,840,000
Accounts receivable, net	106,209,000	105,072,000
Supplies inventory	18,433,000	18,414,000
Deferred income taxes	1,026,000	3,097,000
Prepaid and other current assets	37,151,000	33,602,000
Total current assets	209,935,000	211,025,000
Property and equipment, net	169,006,000	169,895,000
Investments in unconsolidated affiliates and other	19,484,000	16,392,000
Goodwill	1,764,623,000	1,758,970,000
Intangible assets, net	21,093,000	21,662,000
Total assets	2,184,141,000	2,177,944,000
Liabilities and Equity
Current portion of long-term debt	20,285,000	20,844,000
Accounts payable	25,359,000	27,501,000
Accrued salaries and benefits	26,218,000	32,294,000
Other accrued liabilities	12,387,000	9,231,000
Total current liabilities	84,249,000	89,870,000
Long-term debt	564,937,000	583,298,000
Deferred income taxes	185,882,000	176,020,000
Other long-term liabilities	25,753,000	25,503,000
Commitments and contingencies
Noncontrolling interests - redeemable	177,683,000	177,697,000
Preferred stock, no par value, 5,000,000 shares authorized, no shares issued or outstanding	0	0
Equity:
Common stock, no par value, 70,000,000 shares authorized	186,894,000	185,873,000
Retained earnings	595,519,000	578,324,000
Total AmSurg Corp. equity	782,413,000	764,197,000
Noncontrolling interests - non-redeemable	363,224,000	361,359,000
Total equity	1,145,637,000	1,125,556,000
Total liabilities and equity	$ 2,184,141,000	$ 2,177,944,000

XML

Goodwill And Intangible Assets (Summary Of Amortizable Intangible Assets) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 19,262	$ 19,262
Accumulated Amortization	(7,994)	(7,425)
Net	11,268	11,837
Deferred Financing Cost [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	15,814	15,814
Accumulated Amortization	(5,452)	(4,953)
Net	10,362	10,861
Customer And Non Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,448	3,448
Accumulated Amortization	(2,542)	(2,472)
Net	$ 906	$ 976

XML

Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net earnings (loss)	$ 60,114	$ 62,273
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	8,374	8,008
Net (gain) loss on sale of long-lived assets	604	0
(Gain) loss on deconsolidation	(2,045)	(2,237)
Share-based compensation	2,458	2,050
Excess tax benefit from share-based compensation	(1,727)	(288)
Deferred income taxes	11,933	12,929
Equity in earnings of unconsolidated affiliates, net	(764)	(402)
Increase (decrease) in cash and cash equivalents, net of effects of acquisitions and dispositions, due to changes in:
Accounts receivable, net	(1,651)	(1,705)
Supplies inventory	(245)	(201)
Prepaid and other current assets	(3,638)	17
Accounts payable	(3,578)	(3,040)
Accrued expenses and other liabilities	(606)	(4,101)
Other, net	590	562
Net cash flows provided by operating activities	69,819	73,865
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	(5,038)	(252)
Acquisition of property and equipment	(7,038)	(6,110)
Proceeds from sale of interests in surgery centers	1,111	0
Other	(418)	0
Net cash flows used in investing activities	(11,383)	(6,362)
Cash flows from financing activities:
Proceeds from long-term borrowings	31,945	30,870
Repayment on long-term borrowings	(50,853)	(48,211)
Distributions to noncontrolling interests	(43,194)	(43,914)
Proceeds from issuance of common stock upon exercise of stock options	488	5,691
Repurchase of common stock	(2,857)	(16,758)
Capital contributions and ownership transactions by noncontrolling interests	584	559
Excess tax benefit from share-based compensation	1,727	288
Financing cost incurred	0	(13)
Net cash flows provided by (used in) financing activities	(62,160)	(71,488)
Net increase (decrease) in cash and cash equivalents	(3,724)	(3,985)
Cash and cash equivalents, beginning of period	50,840	46,398
Cash and cash equivalents, end of period	$ 47,116	$ 42,413

XML

Guarantor (Balance Sheets) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Assets
Cash and cash equivalents	$ 47,116,000	$ 50,840,000	$ 42,413,000	$ 46,398,000
Accounts receivable, net	106,209,000	105,072,000
Supplies inventory	18,433,000	18,414,000
Deferred income taxes	1,026,000	3,097,000
Prepaid and other current assets	37,151,000	33,602,000
Total current assets	209,935,000	211,025,000
Property and equipment, net	169,006,000	169,895,000
Investments in unconsolidated affiliates and other	19,484,000	16,392,000
Total assets	2,184,141,000	2,177,944,000
Liabilities and Equity
Current portion of long-term debt	20,285,000	20,844,000
Total current liabilities	84,249,000	89,870,000
Long-term debt	564,937,000	583,298,000
Deferred income taxes	185,882,000	176,020,000
Other long-term liabilities	25,753,000	25,503,000
Noncontrolling interests - redeemable	177,683,000	177,697,000
Equity:
Total AmSurg Corp. equity	782,413,000	764,197,000
Noncontrolling interests - non-redeemable	363,224,000	361,359,000
Total equity	1,145,637,000	1,125,556,000
Total liabilities and equity	2,184,141,000	2,177,944,000
Consolidation, Eliminations [Member]
Assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Deferred income taxes	0	0
Prepaid and other current assets	(4,817,000)	(4,362,000)
Total current assets	(4,817,000)	(4,362,000)
Property and equipment, net	0	0
Investments in unconsolidated affiliates and other	(2,928,336,000)	(2,922,178,000)
Goodwill and other intangible assets, net	1,764,622,000	1,758,970,000
Total assets	(1,168,531,000)	(1,167,570,000)
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	(4,627,000)	(3,958,000)
Other accrued liabilities	(190,000)	(404,000)
Total current liabilities	(4,817,000)	(4,362,000)
Long-term debt	(30,822,000)	(31,377,000)
Deferred income taxes	0	0
Other long-term liabilities	0	0
Noncontrolling interests - redeemable	113,992,000	113,993,000
Equity:
Total AmSurg Corp. equity	(1,571,633,000)	(1,568,267,000)
Noncontrolling interests - non-redeemable	324,749,000	322,443,000
Total equity	(1,246,884,000)	(1,245,824,000)
Total liabilities and equity	(1,168,531,000)	(1,167,570,000)
Parent Company [Member]
Assets
Cash and cash equivalents	5,562,000	6,710,000	4,763,000	7,259,000
Accounts receivable, net	0	0
Supplies inventory	52,000	33,000
Deferred income taxes	1,026,000	3,097,000
Prepaid and other current assets	28,618,000	23,993,000
Total current assets	35,258,000	33,833,000
Property and equipment, net	10,129,000	9,829,000
Investments in unconsolidated affiliates and other	1,489,635,000	1,484,974,000
Goodwill and other intangible assets, net	20,185,000	20,684,000
Total assets	1,555,207,000	1,549,320,000
Liabilities and Equity
Current portion of long-term debt	10,714,000	10,714,000
Accounts payable	1,014,000	1,972,000
Other accrued liabilities	24,092,000	27,419,000
Total current liabilities	35,820,000	40,105,000
Long-term debt	543,750,000	561,429,000
Deferred income taxes	185,882,000	176,020,000
Other long-term liabilities	7,342,000	7,569,000
Noncontrolling interests - redeemable	0	0
Equity:
Total AmSurg Corp. equity	782,413,000	764,197,000
Noncontrolling interests - non-redeemable	0	0
Total equity	782,413,000	764,197,000
Total liabilities and equity	1,555,207,000	1,549,320,000
Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Deferred income taxes	0	0
Prepaid and other current assets	0	0
Total current assets	0	0
Property and equipment, net	0	0
Investments in unconsolidated affiliates and other	1,458,185,000	1,453,596,000
Goodwill and other intangible assets, net	0	0
Total assets	1,458,185,000	1,453,596,000
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt	0	0
Deferred income taxes	0	0
Other long-term liabilities	0	0
Noncontrolling interests - redeemable	0	0
Equity:
Total AmSurg Corp. equity	1,458,185,000	1,453,596,000
Noncontrolling interests - non-redeemable	0	0
Total equity	1,458,185,000	1,453,596,000
Total liabilities and equity	1,458,185,000	1,453,596,000
Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	41,554,000	44,130,000	37,650,000	39,139,000
Accounts receivable, net	106,209,000	105,072,000
Supplies inventory	18,381,000	18,381,000
Deferred income taxes	0	0
Prepaid and other current assets	13,350,000	13,971,000
Total current assets	179,494,000	181,554,000
Property and equipment, net	158,877,000	160,066,000
Investments in unconsolidated affiliates and other	0	0
Goodwill and other intangible assets, net	909,000	978,000
Total assets	339,280,000	342,598,000
Liabilities and Equity
Current portion of long-term debt	9,571,000	10,130,000
Accounts payable	28,972,000	29,487,000
Other accrued liabilities	14,703,000	14,510,000
Total current liabilities	53,246,000	54,127,000
Long-term debt	52,009,000	53,246,000
Deferred income taxes	0	0
Other long-term liabilities	18,411,000	17,934,000
Noncontrolling interests - redeemable	63,691,000	63,704,000
Equity:
Total AmSurg Corp. equity	113,448,000	114,671,000
Noncontrolling interests - non-redeemable	38,475,000	38,916,000
Total equity	151,923,000	153,587,000
Total liabilities and equity	339,280,000	342,598,000
Consolidated Entities [Member]
Assets
Goodwill and other intangible assets, net	1,785,716,000	1,780,632,000
Liabilities and Equity
Accounts payable	25,359,000	27,501,000
Other accrued liabilities	$ 38,605,000	$ 41,525,000

XML

Use of Estimates (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Use Of Estimates [Abstract]
Allowances for contractual adjustments	$ 280,582,000		$ 289,937,000
Allowances for accounts receivable	29,120,000		27,862,000
Bad debt expense included in other operating expenses	$ 5,208,000	$ 5,900,000

XML

Basis of Presentation (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Principles of Consolidation

AmSurg Corp. (the “Company”), through its wholly owned subsidiaries, owns interests, primarily 51%, in limited partnerships (“LPs”) and limited liability companies (“LLCs”) which own and operate ambulatory surgery centers (“centers”).The Company does not have an ownership interest in a LP or LLC greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in seven LPs and LLCs, three of which it consolidates as the Company has substantive participation rights and four of which it does not consolidate as the Company’s rights are limited to protective rights only.The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and the consolidated LPs and LLCs. Consolidation of such LPs and LLCs is necessary as the Company’s wholly owned subsidiaries have primarily 51% or more of the financial interest, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the LPs and LLCs, and have control of the entities. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. All LPs and LLCs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, with instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the face of the consolidated statements of earnings and comprehensive income; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows.

As further described in note 11, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2014, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly owned subsidiaries and the partners on a pre-tax basis.

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwiseconsolidate are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates and other in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanyingconsolidated statement of earnings and comprehensive income. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

Each of the Company’s centers have similar economic characteristics and are aggregated into a single component. The Company operates this component as one reportable business segment, the ownership and operation of ambulatory surgery centers.

Reclassifications

Certain prior year amounts in the accompanying consolidated financial statements and these notes have been reclassified to reflect the impact of additional discontinued operations as further discussed in note 5.

XML

Revenue Recognition (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenue Recognition
Percentage of revenues from governmental healthcare programs	25.00%	25.00%

XML

Revenue Recognition (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Revenue Recognition

Center revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, atcertain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from centers are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During each of the three months ended March 31, 2014 and 2013, the Company derived approximately 25% of its revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs. Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements

(1) Basis of Presentation

AmSurg Corp. (the “Company”), through its wholly owned subsidiaries, owns interests, primarily 51%, in limited partnerships (“LPs”) and limited liability companies (“LLCs”) which own and operate ambulatory surgery centers (“centers”).The Company does not have an ownership interest in a LP or LLC greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in seven LPs and LLCs, three of which it consolidates as the Company has substantive participation rights and four of which it does not consolidate as the Company’s rights are limited to protective rights only.The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and the consolidated LPs and LLCs. Consolidation of such LPs and LLCs is necessary as the Company’s wholly owned subsidiaries have primarily 51% or more of the financial interest, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the LPs and LLCs, and have control of the entities. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. All LPs and LLCs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, with instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the face of the consolidated statements of earnings and comprehensive income; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows.

As further described in note 11, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2014, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly owned subsidiaries and the partners on a pre-tax basis.

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwiseconsolidate are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates and other in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanyingconsolidated statement of earnings and comprehensive income. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

Each of the Company’s centers have similar economic characteristics and are aggregated into a single component. The Company operates this component as one reportable business segment, the ownership and operation of ambulatory surgery centers.

These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the unaudited interim consolidated financial statements contained in this report reflect all adjustments, consisting of only normal recurring accruals, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year.

The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2013 Annual Report on Form 10-K. Certain prior year amounts in the accompanying consolidated financial statements and these notes have been reclassified to reflect the impact of additional discontinued operations as further discussed in note 5.

XML

Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Consolidated Balance Sheets
Net of allowance on accounts receivable	$ 29,120	$ 27,862
Preferred stock, par value
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value
Common stock, shares authorized	70,000,000	70,000,000
Common stock, shares outstanding	32,505,000	32,353,000

XML

Commitments And Contingencies

3 Months Ended

Mar. 31, 2014

Commitments And Contingencies

Commitments And Contingencies

(11) Commitments and Contingencies

The Company and its subsidiaries are insured with respect to medical malpractice risk on a claims-made basis. The Company also maintains insurance for general liability, director and officer liability, workers’ compensation liability and property damage. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. Management is not aware of any claims against it or its subsidiaries which would have a material financial impact on the Company.

Certain of the Company’s wholly owned subsidiaries, as general partners in the LPs, are responsible for all debts incurred but unpaid by the LPs. As manager of the operations of the LPs, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions.

In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2014.

On December 27, 2012, the Company entered into a lease agreement with an initial term of 15 years plus renewal options, pursuant to which the Company has agreed to lease an approximately 110,000 square foot building to be constructed in Nashville, Tennessee. The Company intends that the building will serve as its corporate headquarters beginning in 2015. Prior to taking possession, the Company may terminate the agreement if the landlord fails to satisfy certain construction milestones.  The Company’s annual rental obligation at the inception of the lease, which will occur upon completion of construction currently estimated to occur in late 2014, is approximately $2,300,000 and increases by 1.9% annually thereafter during the initial term. In addition to base rent, the Company will pay additional rent consisting of, among other things, operating expenses, real estate taxes and insurance costs. The landlord will provide the Company with an allowance of approximately $4,400,000 for certain interior tenant improvements.

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Entity Registrant Name	AMSURG CORP
Entity Central Index Key	0000895930
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		32,531,056

XML

Recent Accounting Pronouncements

3 Months Ended

Mar. 31, 2014

Recent Accounting Pronouncements [Abstract]

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

(12) Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted. From time to time, the Company will dispose of certain of its centers due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those centers. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. When adopted, this ASU will require the Company to record the results of operations and the associated gain or loss from similar dispositions as a component of continuing operations. The Company does not believe this ASU will have a material impact on the Company’s consolidated financial position or cash flows.

XML

Consolidated Statements Of Earnings (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Consolidated Statements Of Earnings
Revenues	$ 263,107	$ 258,189
Operating expenses:
Salaries and benefits	83,194	80,958
Supply cost	38,720	37,213
Other operating expenses	55,269	52,727
Depreciation and amortization	8,374	8,008
Total operating expenses	185,557	178,906
Gain (loss) on deconsolidation	2,045	2,237
Equity in earnings of unconsolidated affiliates	764	402
Operating income	80,359	81,922
Interest expense	6,963	7,542
Earnings from continuing operations before income taxes	73,396	74,380
Income tax expense	13,057	12,269
Net earnings from continuing operations	60,339	62,111
Discontinued operations:
Earnings (loss) from operations of discontinued interests in surgery centers, net of income tax	137	162
Gain (loss) on disposal of discontinued interests in surgery centers, net of income tax	(362)	0
Net earnings (loss) from discontinued operations	(225)	162
Net earnings and comprehensive income	60,114	62,273
Less net earnings and comprehensive income attributable to noncontrolling interests:
Net earnings from continuing operations	42,835	44,361
Net earnings (loss) from discontinued operations	84	101
Total net earnings and comprehensive income attributable to noncontrolling interests	42,919	44,462
Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	17,195	17,811
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	17,504	17,750
Discontinued operations, net of income tax, attributable to AmSurg Corp.	(309)	61
Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$ 17,195	$ 17,811
Earnings per share-basic:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders	$ 0.55	$ 0.57
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$ (0.01)	$ 0
Net earnings attributable to AmSurg Corp. common shareholders	$ 0.54	$ 0.57
Earnings per share-diluted:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders	$ 0.55	$ 0.56
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$ (0.01)	$ 0
Net earnings attributable to AmSurg Corp. common shareholders	$ 0.54	$ 0.56
Weighted average number of shares and share equivalents outstanding:
Basic	31,716	31,217
Diluted	32,120	31,881

XML

Goodwill And Intangible Assets

3 Months Ended

Mar. 31, 2014

Goodwill And Intangible Assets

Goodwill And Intangible Assets

(6) Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the three months ended March 31, 2014are as follows (in thousands):

Balance as of December 31, 2013	$	1,758,970
Goodwill acquired, including post acquisition adjustments		8,328
Goodwill disposed, including impact of deconsolidation transaction		(2,675)
Balance as of March 31, 2014	$	1,764,623

Amortizable intangible assets at March 31, 2014and December 31, 2013 consisted of the following (in thousands):

		March 31, 2014						December 31, 2013
		Gross						Gross
		Carrying		Accumulated				Carrying		Accumulated
		Amount		Amortization		Net		Amount		Amortization		Net
Deferred financing cost		$	15,814	$	(5,452)	$	10,362	$	15,814	$	(4,953)	$	10,861
Agreements, contracts and other intangible assets			3,448		(2,542)		906		3,448		(2,472)		976
	Total amortizable intangible assets	$	19,262	$	(7,994)	$	11,268	$	19,262	$	(7,425)	$	11,837

Amortization of intangible assets for the three months ended March 31, 2014 and 2013 was $569,000 and $545,000, respectively. Estimated amortization of intangible assets for the remainder of 2014 and the following five years and thereafter is $1,682,000, $2,241,000, $2,240,000, $1,986,000, $1,423,000, $859,000 and $837,000, respectively. The Company expects to recognize amortization of intangible assets over a weighted average period of 5.5 years with no expected residual values.

At March 31, 2014and December 31, 2013, other non-amortizable intangible assets related to restrictive covenant arrangements were $9,825,000, respectively.

XML

Dispositions

3 Months Ended

Mar. 31, 2014

Dispositions

Dispositions

(5) Dispositions

During the three months ended March 31, 2014 and the year ended December 31, 2013, the Company initiated the disposition of certain of its centers due to management’s assessment of the Company’s strategy in the market and due to the limited growth opportunities at these centers. Results of operations (net of income tax) of the centers discontinued for the three months ended March 31, 2014and 2013are as follows (in thousands):

	Three Months Ended March 31,
	2014		2013
Cash proceeds from disposal	$	1,147	$	-
Net (loss) earnings from discontinued operations		(225)		162
Net (loss) earnings from discontinued operations attributable to AmSurg Corp.		(309)		61

The results of operations of discontinued centershave been classified as discontinued operations in all periods presented. Results of operations of the combined discontinued centers for the three months ended March 31, 2014 and 2013are as follows (in thousands):

	Three Months Ended March 31,
	2014		2013
Revenues	$	1,048	$	1,872
Earnings before income taxes		172		209
Net earnings		137		162

XML

Use of Estimates (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

XML

Supplemental Cash Flow Information

3 Months Ended

Mar. 31, 2014

Supplemental Cash Flow Information

Supplemental Cash Flow Information

(13) Supplemental Cash Flow Information

Supplemental cash flow information for the three months ended March 31, 2014 and 2013 is as follows (in thousands):

		Three Months Ended March 31,
		2014		2013
Cash paid during the period for:
	Interest	$	3,132	$	3,547
	Income taxes, net of refunds		65		69
Non-cash investing and financing activities:
	Increase (decrease) in accounts payable associated with acquisition of property and equipment		1,111		(675)
	Capital lease obligations		116		-

XML

Shareholders' Equity

3 Months Ended

Mar. 31, 2014

Shareholders' Equity

Shareholders' Equity

(9) Shareholders’ Equity

a. Common Stock

On April 24, 2012, the Board of Directors authorized a stock purchase program for up to $40,000,000 of the Company’s shares of common stock. The Company completed this repurchase program in August 2013. On August 9, 2013, the Board of Directors authorized a stock purchase program for up to $40,000,000 of the Company’s shares of common stock to be purchased through February 9, 2015. As of March 31, 2014, there was approximately $27,100,000 available under the stock repurchase program.

During the three months ended March 31, 2014, the Company did not purchase any shares under the stock repurchase program. During the three months endedMarch 31, 2013, the Company purchased 438,668 shares of the Company’s common stock for approximately $13,943,000, at an average price of $31.76 per share,in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company’s stock incentive plans.

In addition, the Company repurchases shares to cover payroll withholding taxes in connection with the vesting of restricted stock awards in accordance with the restricted stock agreements. During the three months ended March 31, 2014, and 2013, the Company repurchased 68,014 shares and 89,788 shares, respectively, of common stock for approximately $2,857,000 and $2,815,000, respectively.

b. Stock Incentive Plans

In May 2006, the Company adopted the AmSurg Corp. 2006 Stock Incentive Plan. The Company also has options outstanding under the AmSurg Corp. 1997 Stock Incentive Plan, under which no additional awards may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At March 31, 2014, 2,760,250 shares were authorized for grant under the 2006 Stock Incentive Plan and 763,445 shares were available for future equity grants, including 601,327 shares available for issuance as restricted stock. Restricted stock granted to outside directors prior to 2012 vested over a two year period and restricted stock granted to outside directors during 2012 and after vest over a one year period. Restricted stock granted to employees during 2010 and thereafter vests over four years in three equal installments beginning on the second anniversary of the date of grant. Restricted stock granted to employees prior to 2010 vests at the end of four years from the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date. Under Company policy, shares held by outside directors and senior management are subject to certain holding restrictions.

No options have been issued subsequent to 2008 and all outstanding options are fully vested.Options were granted at market value on the date of the grant and vested over four years.Outstanding options have a term of ten years from the date of grant.

Other information pertaining to share-based activity during the three months ended March 31, 2014and 2013 was as follows (in thousands):

	Three Months Ended March 31,
	2014		2013
Share-based compensation expense	$	2,458	$	2,050
Fair value of shares vested		9,175		9,182
Cash received from option exercises		488		5,691
Tax benefit from option exercises		1,727		288

As of March 31, 2014, the Company had total unrecognized compensation cost of approximately $13,227,000 related to non-vested awards, which the Company expects to recognize through 2018 and over a weighted average period of 1.2 years.

For the period ended March 31, 2014 and 2013, there were no options that were anti-dilutive.

A summary of the status of non-vested restricted shares at March 31, 2014 and changes during the three months ended March 31, 2014 is as follows:

			Weighted
		Number	Average
		of Shares	Grant Price
Non-vested shares at December 31, 2013		743,869	$	26.54
	Shares granted	200,391		42.38
	Shares vested	(218,405)		21.62
Non-vested shares at March 31, 2014		725,855	$	32.40

A summary of stock option activity for the three months ended March 31, 2014 is summarized as follows:

					Weighted
					Average
			Weighted		Remaining
		Number	Average		Contractual
		of Shares	Exercise Price		Term (in years)
Outstanding at December 31, 2013		270,464	$	23.16	2.5
	Options exercised with total intrinsic value of $488,000	(19,921)		24.49
Outstanding at March 31, 2014 with aggregate intrinsic value of $6,020,000		250,543	$	23.05	2.2
Vested at March 31, 2014 with aggregate intrinsic value of $6,020,000		250,543	$	23.05	2.2
Exercisable at March 31, 2014 with aggregate intrinsic value of $6,020,000		250,543	$	23.05	2.2

The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at March 31, 2014 exercised their options at the Company’s closing stock price on March 31, 2014.

c. Earnings per Share

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

		Three Months Ended March 31,
		Earnings		Shares	Per Share
		(Numerator)		(Denominator)	Amount
2014:
Net earnings from continuing operations attributable to AmSurg Corp. per common share (basic)		$	17,504	31,716	$	0.55
Effect of dilutive securities options and non-vested shares			-	404
	Net earnings from continuing operations attributable to AmSurg Corp. per common share (diluted)	$	17,504	32,120	$	0.55
Net earnings attributable to AmSurg Corp. per common share (basic)		$	17,195	31,716	$	0.54
Effect of dilutive securities options and non-vested shares			-	404
	Net earnings attributable to AmSurg Corp. per common share (diluted)	$	17,195	32,120	$	0.54
2013:
Net earnings from continuing operations attributable to AmSurg Corp. per common share (basic)		$	17,750	31,217	$	0.57
Effect of dilutive securities options and non-vested shares			-	664
	Net earnings from continuing operations attributable to AmSurg Corp. per common share (diluted)	$	17,750	31,881	$	0.56
Net earnings attributable to AmSurg Corp. per common share (basic)		$	17,811	31,217	$	0.57
Effect of dilutive securities options and non-vested shares			-	664
	Net earnings attributable to AmSurg Corp. per common share (diluted)	$	17,811	31,881	$	0.56

XML

Guarantor (Income Statements) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Condensed Financial Statements, Captions [Line Items]
Revenues	$ 263,107	$ 258,189
Operating expenses:
Salaries and benefits	83,194	80,958
Supply cost	38,720	37,213
Other operating expenses	55,269	52,727
Depreciation and amortization	8,374	8,008
Total operating expenses	185,557	178,906
Gain (loss) on deconsolidation	2,045	2,237
Equity in earnings of unconsolidated affiliates	764	402
Operating income	80,359	81,922
Interest expense	6,963	7,542
Earnings from continuing operations before income taxes	73,396	74,380
Income tax expense	13,057	12,269
Net earnings from continuing operations	60,339	62,111
Net earnings (loss) from discontinued operations	(225)	162
Net earnings (loss)	60,114	62,273
Less net earnings and comprehensive income attributable to noncontrolling interests:
Net earnings from continuing operations	42,835	44,361
Net earnings (loss) from discontinued operations	84	101
Total net earnings attributable to noncontrolling interests	42,919	44,462
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,195	17,811
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	17,504	17,750
Discontinued operations, net of income tax, attributable to AmSurg Corp.	(309)	61
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,195	17,811
Consolidation, Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	(4,609)	(4,238)
Operating expenses:
Salaries and benefits	(121)	(113)
Supply cost	0	0
Other operating expenses	(4,488)	(4,125)
Depreciation and amortization	0	0
Total operating expenses	(4,609)	(4,238)
Gain (loss) on deconsolidation	(2,045)	(2,237)
Equity in earnings of unconsolidated affiliates	(95,340)	(99,508)
Operating income	(97,385)	(101,745)
Interest expense	0	0
Earnings from continuing operations before income taxes	(97,385)	(101,745)
Income tax expense	0	0
Net earnings from continuing operations	(97,385)	(101,745)
Net earnings (loss) from discontinued operations	0	0
Net earnings (loss)	(97,385)	(101,745)
Less net earnings and comprehensive income attributable to noncontrolling interests:
Net earnings from continuing operations	0	0
Net earnings (loss) from discontinued operations	0	0
Total net earnings attributable to noncontrolling interests	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	(97,385)	(101,745)
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	(97,385)	(101,745)
Discontinued operations, net of income tax, attributable to AmSurg Corp.	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	(97,385)	(101,745)
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	6,127	5,716
Operating expenses:
Salaries and benefits	14,485	15,421
Supply cost	0	0
Other operating expenses	4,166	5,060
Depreciation and amortization	825	772
Total operating expenses	19,476	21,253
Gain (loss) on deconsolidation	2,045	2,237
Equity in earnings of unconsolidated affiliates	48,052	49,955
Operating income	36,748	36,655
Interest expense	6,452	6,923
Earnings from continuing operations before income taxes	30,296	29,732
Income tax expense	12,704	11,877
Net earnings from continuing operations	17,592	17,855
Net earnings (loss) from discontinued operations	(397)	(44)
Net earnings (loss)	17,195	17,811
Less net earnings and comprehensive income attributable to noncontrolling interests:
Net earnings from continuing operations	0	0
Net earnings (loss) from discontinued operations	0	0
Total net earnings attributable to noncontrolling interests	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,195	17,811
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	17,592	17,855
Discontinued operations, net of income tax, attributable to AmSurg Corp.	(397)	(44)
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,195	17,811
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	0	0
Operating expenses:
Salaries and benefits	0	0
Supply cost	0	0
Other operating expenses	0	0
Depreciation and amortization	0	0
Total operating expenses	0	0
Gain (loss) on deconsolidation	2,045	2,237
Equity in earnings of unconsolidated affiliates	48,052	49,955
Operating income	50,097	52,192
Interest expense	0	0
Earnings from continuing operations before income taxes	50,097	52,192
Income tax expense	0	0
Net earnings from continuing operations	50,097	52,192
Net earnings (loss) from discontinued operations	0	0
Net earnings (loss)	50,097	52,192
Less net earnings and comprehensive income attributable to noncontrolling interests:
Net earnings from continuing operations	0	0
Net earnings (loss) from discontinued operations	0	0
Total net earnings attributable to noncontrolling interests	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	50,097	52,192
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	50,097	52,192
Discontinued operations, net of income tax, attributable to AmSurg Corp.	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	50,097	52,192
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	261,589	256,711
Operating expenses:
Salaries and benefits	68,830	65,650
Supply cost	38,720	37,213
Other operating expenses	55,591	51,792
Depreciation and amortization	7,549	7,236
Total operating expenses	170,690	161,891
Gain (loss) on deconsolidation	0	0
Equity in earnings of unconsolidated affiliates	0	0
Operating income	90,899	94,820
Interest expense	511	619
Earnings from continuing operations before income taxes	90,388	94,201
Income tax expense	353	392
Net earnings from continuing operations	90,035	93,809
Net earnings (loss) from discontinued operations	172	206
Net earnings (loss)	90,207	94,015
Less net earnings and comprehensive income attributable to noncontrolling interests:
Net earnings from continuing operations	42,835	44,361
Net earnings (loss) from discontinued operations	84	101
Total net earnings attributable to noncontrolling interests	42,919	44,462
Net earnings (loss) attributable to AmSurg Corp. common shareholders	47,288	49,553
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	47,200	49,448
Discontinued operations, net of income tax, attributable to AmSurg Corp.	88	105
Net earnings (loss) attributable to AmSurg Corp. common shareholders	$ 47,288	$ 49,553

XML

Long-Term Debt

3 Months Ended

Mar. 31, 2014

Long-Term Debt

Long-Term Debt

(7)Long-term Debt

Long-term debt at March 31, 2014 and December 31, 2013 was comprised of the following (in thousands):

		March 31,		December 31,
		2014		2013
Revolving credit agreement		$	237,500	$	252,500
Senior Unsecured Notes due 2020 (5.625%)			250,000		250,000
Senior Secured Notes due 2020 (8.04%)			66,964		69,643
Other debt due through 2025			20,193		21,149
Capitalized lease arrangements due through 2026			10,565		10,850
			585,222		604,142
Less current portion			20,285		20,844
	Long-term debt	$	564,937	$	583,298

a. Credit Facility

On June 14, 2013, the Company amended its revolving credit agreement to adjust the interest rate spreads and extend the maturity date by one year. The revolving credit agreement, as amended, permits the Company to borrow up to $475,000,000 at an interest rate equal to, at the Company’s option, the base rate plus 0.25% to 1.00% or LIBOR plus 1.25% to 2.00%, or a combination thereof; provides for a fee of 0.25% to 0.40% of unused commitments; and contains certain covenants relating to the ratio of debt to operating performance measurements, interest coverage ratios and minimum net worth. Borrowings under the revolving credit agreement mature in June 2018 and are secured primarily by a pledge of the stock of the Company’s wholly-owned subsidiaries and the Company’s partnership and membership interests in the LPs and LLCs. The Company was in compliance with the covenants contained in the revolving credit agreement at March 31, 2014.

b. Senior Unsecured Notes

On November 20, 2012, the Company completed a private offering of $250,000,000 aggregate principal amount of 5.625% senior unsecured notes due 2020 (the “Senior Unsecured Notes”). On May 31, 2013 the Company completed an offer to exchange the outstanding Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended. The net proceeds from the issuance of the Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s revolving credit agreement. The Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly owned domestic subsidiaries. The Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020.

Prior to November 30, 2015, the Company may redeem up to 35% of the aggregate principal amount of the Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after November 30, 2015, the Company may redeem the Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:

Period	Redemption Price
2015	104.219%
2016	102.813%
2017	101.406%
2018 and thereafter	100.000%

The Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. The Company was in compliance with the covenants contained in the indenture relating to the Senior Unsecured Notes at March 31, 2014.

c. Senior Secured Notes

The Company issued $75,000,000 principal amount of senior secured notes (the “Senior Secured Notes”) on May 28, 2010 pursuant to a note purchase agreement. The Senior Secured Notes mature on May 28, 2020. The Senior Secured Notes, which were originally issued with a stated interest rate of 6.04%, were amended on November 7, 2012 to allow for the Company’s issuance of the Senior Unsecured Notes, which resulted in an increase in the annual interest rate to 8.04%, and included certain other adjustments to the existing covenants. The Senior Secured Notes are pari passu with the indebtedness under the Company’s revolving credit agreement and the Senior Unsecured Notes and principal payments began in August 2013. The note purchase agreement governing the Senior Secured Notes contains covenants similar to the covenants in the revolving credit agreement and includes a make whole provision in the event of any prepayment of principle. The Company was in compliance with the covenants contained in the note purchase agreement relating to the Senior Secured Notes at March 31, 2014.

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2014

Fair Value Measurements

Fair Value Measurements

(8) Fair Value Measurements

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following hierarchy:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

In determining the fair value of assets and liabilities that are measured on a recurring basis at March 31, 2014 and December 31, 2013, the Company utilized Level 2 inputs to perform such measurements methods, which were commensurate with the market approach. As of March 31, 2014 and December 31, 2013, the fair value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets in the accompanying consolidated balance sheets, was $16,175,000 and $13,313,000, respectively. The fair values were determined using the calculated net asset values obtained from the plan administrator and observable inputs of similar public mutual fund investments (Level 2). There were no transfers to or from Levels 1 and 2 during the three months ended March 31, 2014.

Cash and cash equivalents, receivables and payables are reflected in the financial statements at cost, which approximates fair value. The fair value of fixed rate long-term debt, with a carrying value of $345,253,000, was $365,111,000 at March 31, 2014. The fair value of variable rate long-term debt approximates its carrying value of $239,969,000 at March 31, 2014. With the exception of the Company’s Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company’s Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

XML

Income Taxes

3 Months Ended

Mar. 31, 2014

Income Taxes

Income Taxes

(10) Income Taxes

The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statement of earnings and comprehensive income. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file U.S. federal and various state tax returns. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2010.

XML

Basis of Presentation (Details)	Mar. 31, 2014 Centers
Ownership Interests [Line Items]
Number Of Centers Owned Less Than 51 Percent	7
Consolidated [Member]
Ownership Interests [Line Items]
Number Of Centers Owned Less Than 51 Percent	3
Nonconsolidated [Member]
Ownership Interests [Line Items]
Number Of Centers Owned Less Than 51 Percent	4

XML

Shareholder's Equity (Narrative) (Details) (USD $)	0 Months Ended		3 Months Ended
	Aug. 09, 2013 M	Apr. 24, 2012 Y	Mar. 31, 2014	Mar. 31, 2013
Common Stock:
Stock repurchased program authorized by the board of directors	$ 40,000,000	$ 40,000,000
Period of stock repurchase program, months	18	18
Amount remaining under stock repurchase plan			27,100,000
Stock Incentive Plans:
Number of shares authorized for grant under share incentive plan			2,760,250
Shares available for future grants/issuance under stock incentive plan			763,445
Unrecognized compensation cost on non vested awards			13,227,000
Employee Service Share-based Compensation, Nonvested Awards			1 year 2 months 12 days
Share based payment award shares purchased for award			0	0
Stock Repurchased Under Repurchase Program [Member]
Common Stock:
Repurchase of common stock, shares			0	438,668
Repurchase of common stock			0	13,943,000
Average price per share			$ 0	$ 31.76
Stock Repurchased To Cover Employee Tax Withholdings [Member]
Common Stock:
Repurchase of common stock, shares			68,014	89,788
Repurchase of common stock			$ 2,857,000	$ 2,815,000
Stock Options
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
Options term			10
Restricted Stock [Member]
Stock Incentive Plans:
Shares available for future grants/issuance under stock incentive plan			601,327
Outside Directors [Member] | Restricted Stock [Member] | Period from January 1, 2012 thru current period
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 year
Outside Directors [Member] | Restricted Stock [Member] | Period prior to January 1, 2012
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			2 years
Employees [Member] | Restricted Stock [Member] | Period from January 1, 2010 thru current period
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
Number of installments in restricted stock granted.			3
Employees [Member] | Restricted Stock [Member] | Period prior to January 1, 2010
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years

XML

Subsequent Events

3 Months Ended

Mar. 31, 2014

Subsequent Events

Subsequent Events

(15) Subsequent Events

The Company assessed events occurring subsequent to March 31, 2014 for potential recognition and disclosure in the unaudited consolidated financial statements. No events have occurred that would require adjustment to or disclosure in the unaudited consolidated financial statements.

XML

Income Taxes (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Income Taxes

The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statement of earnings and comprehensive income. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file U.S. federal and various state tax returns. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2010.

XML

Long-Term Debt (Redemption Price) (Details) (Unsecured Debt [Member])	Mar. 31, 2014
Period from November 30, 2015 to November 29, 2016
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	104.219%
Period from November 30, 2016 to November 29, 2017
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	102.813%
Period from November 30, 2017 to November 29, 2018
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	101.406%
Period from November 30, 2018 to November 30, 2020
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	100.00%

XML

Dispositions (Results Of Operations Of Centers Discontinued) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Dispositions
Cash proceeds from disposal	$ 1,147	$ 0
Net earnings (loss) from discontinued operations	(225)	162
Net (loss) gain from discontinued operations attributable to AmSurg Corp.	$ (309)	$ 61

XML

Consolidated Statements Of Changes In Equity (USD $)	Total	Common Stock Including Additional Paid in Capital [Member]	Retained Earnings [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable [Member]
Balance at Dec. 31, 2012		$ 183,867,000	$ 505,621,000	$ 310,978,000	$ 1,000,466,000	$ 175,382,000
Balance (in shares) at Dec. 31, 2012		31,941,000
Issuance of restricted common stock (in shares)		263,000
Cancellation of restricted common stock (in shares)		(14,000)
Stock options exercised		5,691,000			5,691,000
Stock options exercised (in shares)		237,000
Stock repurchased		(16,758,000)			(16,758,000)
Stock repurchased (in shares)		(528,000)
Share-based compensation, value	2,050,000	2,050,000			2,050,000
Tax benefit related to exercise of stock options		1,630,000			1,630,000
Net earnings and comprehensive income	62,273,000		17,811,000	12,232,000	30,043,000	32,230,000
Distributions to noncontrolling interests, net of capital contributions				(11,891,000)	(11,891,000)	(31,823,000)
Purchase of noncontrolling interest, value		(304,000)		(133,000)	(437,000)	(316,000)
Sale of noncontrolling interest, value		(644,000)		1,419,000	775,000	236,000
Acquisitions and other transactions impacting noncontrolling interests				266,000	266,000	0
Disposals and other transactions impacting noncontrolling interests		0		(317,000)	(317,000)
Balance at Mar. 31, 2013		175,532,000	523,432,000	312,554,000	1,011,518,000	175,709,000
Balance (in shares) at Mar. 31, 2013		31,899,000
Balance at Dec. 31, 2013	1,125,556,000	185,873,000	578,324,000	361,359,000	1,125,556,000	177,697,000
Balance (in shares) at Dec. 31, 2013		32,353,000
Issuance of restricted common stock (in shares)		200,000
Stock options exercised		488,000			488,000
Stock options exercised (in shares)	19,921	20,000
Stock repurchased		(2,857,000)			(2,857,000)
Stock repurchased (in shares)		(68,000)
Share-based compensation, value	2,458,000	2,458,000			2,458,000
Tax benefit related to exercise of stock options		1,727,000			1,727,000
Net earnings and comprehensive income	60,114,000		17,195,000	12,219,000	29,414,000	30,700,000
Distributions to noncontrolling interests, net of capital contributions				(12,753,000)	(12,753,000)	(30,441,000)
Purchase of noncontrolling interest, value		286,000		(286,000)	0	0
Sale of noncontrolling interest, value		(1,081,000)		1,665,000	584,000	0
Acquisitions and other transactions impacting noncontrolling interests				3,976,000	3,976,000
Disposals and other transactions impacting noncontrolling interests				(2,956,000)	(2,956,000)	(273,000)
Balance at Mar. 31, 2014	$ 1,145,637,000	$ 186,894,000	$ 595,519,000	$ 363,224,000	$ 1,145,637,000	$ 177,683,000
Balance (in shares) at Mar. 31, 2014		32,505,000

XML

Acquisitions

3 Months Ended

Mar. 31, 2014

Business Combinations [Abstract]

Acquisitions

(4) Acquisitions and Investments in Unconsolidated Affiliates

As a significant part of its growth strategy, the Company primarily acquires controlling interests in centers. The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value.

During the three months ended March 31, 2014 the Company, through a wholly owned subsidiary, acquired a controlling interest in one center.The aggregate amount paid for the center acquired during the three months ended March 31, 2014 was approximately $5,038,000, net of cash acquired, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility. The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers’ favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model.

In conjunction with the Company’s acquisition of 17 centers from National Surgical Care, Inc. (“NSC”) on September 1, 2011, the Company agreed to pay as additional consideration an amount up to $7,500,000 based on a multiple of the excess earnings over the targeted earnings of the acquired centers, if any, from the period of January 1, 2012 to December 31, 2012. During the three months ended March 31, 2013, the Company paid NSC $2,744,000 as final settlement of the additional consideration due in accordance with the purchase agreement.

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisition completed in the three months ended March 31, 2014 and 2013, including post acquisition date adjustments recorded to finalize purchase price allocations, are as follows (in thousands):

		Three Months Ended March 31,
		2014		2013
Accounts receivable		$	417	$	-
Supplies, inventory, prepaid and other current assets			81		-
Property and equipment			429		-
Goodwill			8,260		-
Accounts payable			(125)		-
Other accrued liabilities			(39)		-
	Total fair value		9,023		-
	Less: Fair value attributable to noncontrolling interests		3,985		-
	Acquisition date fair value of total consideration transferred	$	5,038	$	-

Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests in centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. For the three months ended March 31, 2014 approximately $4,670,000 of goodwill recorded was deductible for tax purposes. The acquisition related costs incurred by the Company were not significant for the three months ended March 31, 2014 and 2013,respectively.

Revenues and net earnings included in the three months ended March 31, 2014 and 2013 associated with this acquisition are as follows (in thousands):

		Three Months Ended March 31,
		2014		2013
Revenues		$	1,031	$	-
Net earnings			245		-
Less: Net earnings attributable to noncontrolling interests			151		-
	Net earnings attributable to AmSurg Corp. common shareholders	$	94	$	-

The unaudited consolidated pro forma results for the three months ended March 31, 2014 and 2013, assuming all 2014acquisitions had been consummated on January 1, 2013and all 2013 acquisitions had been consummated on January 1, 2012, are as follows (in thousands, except per share data):

			Three Months Ended March 31,
			2014		2013
Revenues			$	263,107	$	270,371
Net earnings				60,114		65,385
Amounts attributable to AmSurg Corp. common shareholders:
	Net earnings from continuing operations			17,504		18,830
	Net earnings			17,195		18,891
	Net earnings from continuing operations per common share:
		Basic	$	0.55	$	0.60
		Diluted	$	0.54	$	0.59
	Net earnings:
		Basic	$	0.54	$	0.61
		Diluted	$	0.54	$	0.59
	Weighted average number of shares and share equivalents:
		Basic		31,716		31,217
		Diluted		32,120		31,881

During the three months ended March 31, 2014, the Company entered into a transaction whereby it contributed a controlling interest in one center in exchange for $600,000 and a noncontrolling interest in an entity jointly owned by a hospital that, after the completion of the transaction, controls the contributed center. During the three months ended March 31, 2013, the Company entered into a transaction whereby it contributed cash of $252,000 plus a controlling interest in one center in exchange for a noncontrolling interest in an entity jointly owned by a hospital that, after the completion of the transaction, controlled the contributed center and one additional center. Management of the Company believes these structures provide both economies of scale and potential future growth opportunities in the markets in which the centers are located. As a result of these transactions, the Company recorded in the accompanying consolidated balance sheets as a component of investments in unconsolidated affiliates and other, the fair value of the noncontrolling interest in the entities which control the contributed centers of approximately $1,238,000 and $5,200,000 as of the three months ended March 31, 2014 and 2013, respectively. Accordingly, during the three months ended March 31, 2014 and 2013, the Company recognized a gain on deconsolidation in the accompanying consolidated statements of earnings and comprehensive income of approximately $2,045,000 and $2,237,000, respectively. In each of these transactions, the gain on deconsolidation was determined based on the difference between the fair value of the Company’s noncontrolling interest in the new entity and the carrying value of both the tangible and intangible assets of the contributed centers immediately prior to each transaction.

XML

Supplemental Cash Flow Information (Summary Of Supplemental Cash Flow Information) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Paid During The Period For
Interest	$ 3,132	$ 3,547
Income taxes, net of refunds	65	69
Noncash Investing and Financing Activities
Increase (decrease) in accounts payable associated with acquisition of property and equipment	1,111	(675)
Capital lease obligations	$ 116	$ 0

XML

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2014

Business Combinations [Abstract]

Fair Value Of Total Consideration Transferred And Major Class Of Consideration

		Three Months Ended March 31,
		2014		2013
Accounts receivable		$	417	$	-
Supplies, inventory, prepaid and other current assets			81		-
Property and equipment			429		-
Goodwill			8,260		-
Accounts payable			(125)		-
Other accrued liabilities			(39)		-
	Total fair value		9,023		-
	Less: Fair value attributable to noncontrolling interests		3,985		-
	Acquisition date fair value of total consideration transferred	$	5,038	$	-

Revenues And Net Earnings Associated With Acquisitions

		Three Months Ended March 31,
		2014		2013
Revenues		$	1,031	$	-
Net earnings			245		-
Less: Net earnings attributable to noncontrolling interests			151		-
	Net earnings attributable to AmSurg Corp. common shareholders	$	94	$	-

Consolidated Pro Forma Results Of Acquisition

			Three Months Ended March 31,
			2014		2013
Revenues			$	263,107	$	270,371
Net earnings				60,114		65,385
Amounts attributable to AmSurg Corp. common shareholders:
	Net earnings from continuing operations			17,504		18,830
	Net earnings			17,195		18,891
	Net earnings from continuing operations per common share:
		Basic	$	0.55	$	0.60
		Diluted	$	0.54	$	0.59
	Net earnings:
		Basic	$	0.54	$	0.61
		Diluted	$	0.54	$	0.59
	Weighted average number of shares and share equivalents:
		Basic		31,716		31,217
		Diluted		32,120		31,881

XML

Acquisitions (Fair Value Of Total Consideration Transferred And Major Class Of Consideration) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014 Series of Individually Immaterial Business Acquisitions [Member]	Mar. 31, 2013 Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable			$ 417	$ 0
Supplies, inventory, prepaid and other current assets			81	0
Property and equipment			429	0
Goodwill	1,764,623	1,758,970	8,260	0
Accounts payable			(125)	0
Other accrued liabilities			(39)	0
Total fair value			9,023	0
Less: Fair value attributable to noncontrolling interests			3,985	0
Acquisition date fair value of total consideration transferred			$ 5,038	$ 0

XML

Guarantor

3 Months Ended

Mar. 31, 2014

Condensed Consolidating Financial Information

Condensed Consolidating Financial Information

(14) Financial Information for the Company and Its Subsidiaries

The Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly owned domestic subsidiaries. The Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered." The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.

Condensed Consolidating Balance Sheet - March 31, 2014 (In thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	5,562	$	-	$	41,554	$	-	$	47,116
	Accounts receivable, net				-		-		106,209		-		106,209
	Supplies inventory				52		-		18,381		-		18,433
	Deferred income taxes				1,026		-		-		-		1,026
	Prepaid and other current assets				28,618		-		13,350		(4,817)		37,151
		Total current assets			35,258		-		179,494		(4,817)		209,935
Property and equipment, net					10,129		-		158,877		-		169,006
Investments in unconsolidated affiliates and other					1,489,635		1,458,185		-		(2,928,336)		19,484
Goodwill and intangible assets, net					20,185		-		909		1,764,622		1,785,716
			Total assets	$	1,555,207	$	1,458,185	$	339,280	$	(1,168,531)	$	2,184,141
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	10,714	$	-	$	9,571	$	-	$	20,285
	Accounts payable				1,014		-		28,972		(4,627)		25,359
	Accrued liabilities				24,092		-		14,703		(190)		38,605
		Total current liabilities			35,820		-		53,246		(4,817)		84,249
Long-term debt					543,750		-		52,009		(30,822)		564,937
Deferred income taxes					185,882		-		-		-		185,882
Other long-term liabilities					7,342		-		18,411		-		25,753
Noncontrolling interests – redeemable					-		-		63,691		113,992		177,683
Equity:
		Total AmSurg Corp. equity			782,413		1,458,185		113,448		(1,571,633)		782,413
		Noncontrolling interests – non-redeemable			-		-		38,475		324,749		363,224
		Total equity			782,413		1,458,185		151,923		(1,246,884)		1,145,637
			Total liabilities and equity	$	1,555,207	$	1,458,185	$	339,280	$	(1,168,531)	$	2,184,141

Condensed Consolidating Balance Sheet - December 31, 2013 (In thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	6,710	$	-	$	44,130	$	-	$	50,840
	Accounts receivable, net				-		-		105,072		-		105,072
	Supplies inventory				33		-		18,381		-		18,414
	Deferred income taxes				3,097		-		-		-		3,097
	Prepaid and other current assets				23,993		-		13,971		(4,362)		33,602
		Total current assets			33,833		-		181,554		(4,362)		211,025
Property and equipment, net					9,829		-		160,066		-		169,895
Investments in unconsolidated affiliates and other					1,484,974		1,453,596		-		(2,922,178)		16,392
Goodwill and intangible assets, net					20,684		-		978		1,758,970		1,780,632
			Total assets	$	1,549,320	$	1,453,596	$	342,598	$	(1,167,570)	$	2,177,944
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	10,714	$	-	$	10,130	$	-	$	20,844
	Accounts payable				1,972		-		29,487		(3,958)		27,501
	Accrued liabilities				27,419		-		14,510		(404)		41,525
		Total current liabilities			40,105		-		54,127		(4,362)		89,870
Long-term debt					561,429		-		53,246		(31,377)		583,298
Deferred income taxes					176,020		-		-		-		176,020
Other long-term liabilities					7,569		-		17,934		-		25,503
Noncontrolling interests – redeemable					-		-		63,704		113,993		177,697
Equity:
		Total AmSurg Corp. equity			764,197		1,453,596		114,671		(1,568,267)		764,197
		Noncontrolling interests – non-redeemable			-		-		38,916		322,443		361,359
		Total equity			764,197		1,453,596		153,587		(1,245,824)		1,125,556
			Total liabilities and equity	$	1,549,320	$	1,453,596	$	342,598	$	(1,167,570)	$	2,177,944

Condensed Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2014 (In thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues				$	6,127	$	-	$	261,589	$	(4,609)	$	263,107
Operating expenses:
	Salaries and benefits				14,485		-		68,830		(121)		83,194
	Supply cost				-		-		38,720		-		38,720
	Other operating expenses				4,166		-		55,591		(4,488)		55,269
	Depreciation and amortization				825		-		7,549		-		8,374
		Total operating expenses			19,476		-		170,690		(4,609)		185,557
Gain on deconsolidation					2,045		2,045		-		(2,045)		2,045
Equity in earnings of unconsolidated affiliates					48,052		48,052		-		(95,340)		764
		Operating income			36,748		50,097		90,899		(97,385)		80,359
Interest expense					6,452		-		511		-		6,963
	Earnings from continuing operations before income taxes				30,296		50,097		90,388		(97,385)		73,396
Income tax expense					12,704		-		353		-		13,057
	Net earnings from continuing operations				17,592		50,097		90,035		(97,385)		60,339
	Net earnings (loss) from discontinued operations				(397)		-		172		-		(225)
		Net earnings and comprehensive income			17,195		50,097		90,207		(97,385)		60,114
Less net earnings and comprehensive income attributable to noncontrolling interests:
	Net earnings from continuing operations				-		-		42,835		-		42,835
	Net earnings from discontinued operations				-		-		84		-		84
		Total net earnings and comprehensive income attributable to noncontrolling interests			-		-		42,919		-		42,919
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$	17,195	$	50,097	$	47,288	$	(97,385)	$	17,195
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax			$	17,592	$	50,097	$	47,200	$	(97,385)	$	17,504
	Discontinued operations, net of income tax				(397)		-		88		-		(309)
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$	17,195	$	50,097	$	47,288	$	(97,385)	$	17,195

Condensed Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2013 (In thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues				$	5,716	$	-	$	256,711	$	(4,238)	$	258,189
Operating expenses:
	Salaries and benefits				15,421		-		65,650		(113)		80,958
	Supply cost				-		-		37,213		-		37,213
	Other operating expenses				5,060		-		51,792		(4,125)		52,727
	Depreciation and amortization				772		-		7,236		-		8,008
		Total operating expenses			21,253		-		161,891		(4,238)		178,906
Gain on deconsolidation					2,237		2,237		-		(2,237)		2,237
Equity in earnings of unconsolidated affiliates					49,955		49,955		-		(99,508)		402
		Operating income			36,655		52,192		94,820		(101,745)		81,922
Interest expense					6,923		-		619		-		7,542
	Earnings from continuing operations before income taxes				29,732		52,192		94,201		(101,745)		74,380
Income tax expense					11,877		-		392		-		12,269
	Net earnings from continuing operations				17,855		52,192		93,809		(101,745)		62,111
	Net earnings (loss) from discontinued operations				(44)		-		206		-		162
		Net earnings and comprehensive income			17,811		52,192		94,015		(101,745)		62,273
Less net earnings and comprehensive income attributable to noncontrolling interests:
	Net earnings from continuing operations				-		-		44,361		-		44,361
	Net earnings from discontinued operations				-		-		101		-		101
		Total net earnings and comprehensive income attributable to noncontrolling interests			-		-		44,462		-		44,462
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$	17,811	$	52,192	$	49,553	$	(101,745)	$	17,811
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax			$	17,855	$	52,192	$	49,448	$	(101,745)	$	17,750
	Discontinued operations, net of income tax				(44)		-		105		-		61
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders	$	17,811	$	52,192	$	49,553	$	(101,745)	$	17,811

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2014 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by operating activities	$	18,482	$	48,096	$	96,257	$	(93,016)	$	69,819
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(5,082)		-		44		(5,038)
	Acquisition of property and equipment			(1,237)		-		(5,801)		-		(7,038)
	Proceeds from sale of interests in surgery centers			-		1,111		-		-		1,111
	Other			(629)		211		-		-		(418)
		Net cash flows used in investing activities		(1,866)		(3,760)		(5,801)		44		(11,383)
Cash flows from financing activities:
	Proceeds from long-term borrowings			30,000		-		1,945		-		31,945
	Repayment on long-term borrowings			(47,679)		-		(3,174)		-		(50,853)
	Distributions to owners, including noncontrolling interests			-		(44,920)		(91,290)		93,016		(43,194)
	Changes in intercompany balances with affiliates, net			556		-		(556)		-		-
	Other financing activities, net			(641)		584		43		(44)		(58)
		Net cash flows used in financing activities		(17,764)		(44,336)		(93,032)		92,972		(62,160)
Net decrease in cash and cash equivalents				(1,148)		-		(2,576)		-		(3,724)
Cash and cash equivalents, beginning of period				6,710		-		44,130		-		50,840
Cash and cash equivalents, end of period			$	5,562	$	-	$	41,554	$	-	$	47,116

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2013 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by operating activities	$	23,940	$	49,577	$	99,411	$	(99,063)	$	73,865
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(242)		-		(10)		(252)
	Acquisition of property and equipment			(853)		-		(5,257)		-		(6,110)
		Net cash flows used in investing activities		(853)		(242)		(5,257)		(10)		(6,362)
Cash flows from financing activities:
	Proceeds from long-term borrowings			29,700		-		1,170		-		30,870
	Repayment on long-term borrowings			(45,024)		-		(3,187)		-		(48,211)
	Distributions to owners, including noncontrolling interests			-		(49,486)		(93,491)		99,063		(43,914)
	Changes in intercompany balances with affiliates, net			533		-		(533)		-		-
	Other financing activities, net			(10,792)		151		398		10		(10,233)
		Net cash flows used in financing activities		(25,583)		(49,335)		(95,643)		99,073		(71,488)
Net decrease in cash and cash equivalents				(2,496)		-		(1,489)		-		(3,985)
Cash and cash equivalents, beginning of period				7,259		-		39,139		-		46,398
Cash and cash equivalents, end of period			$	4,763	$	-	$	37,650	$	-	$	42,413